Search Page

1

Cite

Share

PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.

Hillmann P, Fabbro D. Hillmann P, et al. Among authors: fabbro d. Int J Mol Sci. 2019 Nov 18;20(22):5792. doi: 10.3390/ijms20225792. Int J Mol Sci. 2019. PMID: 31752127 Free PMC article. Review.

Cite

Share

2

Cite

Share

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T, Groell JM, Grotzfeld RM, Hassan AQ, Henry C, Iyer V, Jones D, Lombardo F, Loo A, Manley PW, Pellé X, Rummel G, Salem B, Warmuth M, Wylie AA, Zoller T, Marzinzik AL, Furet P. Schoepfer J, et al. Among authors: fabbro d. J Med Chem. 2018 Sep 27;61(18):8120-8135. doi: 10.1021/acs.jmedchem.8b01040. Epub 2018 Sep 7. J Med Chem. 2018. PMID: 30137981

Cite

Share

3

Cite

Share

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Furet P, Guagnano V, Fairhurst RA, Imbach-Weese P, Bruce I, Knapp M, Fritsch C, Blasco F, Blanz J, Aichholz R, Hamon J, Fabbro D, Caravatti G. Furet P, et al. Among authors: fabbro d. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8. doi: 10.1016/j.bmcl.2013.05.007. Epub 2013 May 14. Bioorg Med Chem Lett. 2013. PMID: 23726034

Cite

Share

4

Cite

Share

Author errata.

Meyer T, Regenass U, Fabbro D, Alteri E, Rösel J, Müller M, Caravatti G, Matter A. Meyer T, et al. Among authors: fabbro d. Int J Cancer. 1999 May 17;81(4):669. doi: 10.1002/(sici)1097-0215(19990517)81:4<669::aid-ijc26>3.0.co;2-f. Int J Cancer. 1999. PMID: 10336343 Free article. No abstract available.

Cite

Share

5

Cite

Share

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Harding SD, Faccenda E, Southan C, Pawson AJ, Maffia P, Alexander SPH, Davenport AP, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA. Harding SD, et al. Among authors: fabbro d. Immunology. 2020 May;160(1):10-23. doi: 10.1111/imm.13175. Epub 2020 Mar 2. Immunology. 2020. PMID: 32020584 Free PMC article. Review.

Cite

Share

6

Cite

Share

Notch Inhibition in Cancer: Challenges and Opportunities.

Fabbro D, Bauer M, Murone M, Lehal R. Fabbro D, et al. Chimia (Aarau). 2020 Oct 28;74(10):779-783. doi: 10.2533/chimia.2020.779. Chimia (Aarau). 2020. PMID: 33115560

Cite

Share

7

Cite

Share

[PKC 412].

Lansiaux A, Fabbro D, Meyer T, Hamy F, Bailly C. Lansiaux A, et al. Among authors: fabbro d. Bull Cancer. 1999 Jul-Aug;86(7-8):614-7. Bull Cancer. 1999. PMID: 10477377 Free article. Review. French. No abstract available.

Cite

Share

8

Cite

Share

An interview with Doriano Fabbro, Ph.D., Novartis Biomedical Research Institute. Interviewed by Vicki Glaser.

Fabbro D. Fabbro D. Assay Drug Dev Technol. 2004 Apr;2(2):109-14. doi: 10.1089/154065804323056440. Assay Drug Dev Technol. 2004. PMID: 15165506 No abstract available.

Cite

Share

9

Cite

Share

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes.

Alexander SPH, Fabbro D, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. Alexander SPH, et al. Among authors: fabbro d. Br J Pharmacol. 2019 Dec;176 Suppl 1(Suppl 1):S297-S396. doi: 10.1111/bph.14752. Br J Pharmacol. 2019. PMID: 31710714 Free PMC article. Review.

Cite

Share

10

Cite

Share

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors.

Alexander SPH, Fabbro D, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. Alexander SPH, et al. Among authors: fabbro d. Br J Pharmacol. 2019 Dec;176 Suppl 1(Suppl 1):S247-S296. doi: 10.1111/bph.14751. Br J Pharmacol. 2019. PMID: 31710716 Free PMC article. Review.

Cite

Share